{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:53:18Z","timestamp":1791395598296,"version":"4.3.3"},"reference-count":16,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002301","name":"the European Regional Development Fund","doi-asserted-by":"publisher","award":["MOBTT39"],"award-info":[{"award-number":["MOBTT39"]}],"id":[{"id":"10.13039\/501100002301","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Background: Enterovirus infections affect people around the world, causing a range of illnesses, from mild fevers to severe, potentially fatal conditions. There are no approved treatments for enterovirus infections. Methods: We have tested our library of broad-spectrum antiviral agents (BSAs) against echovirus 1 (EV1) in human adenocarcinoma alveolar basal epithelial A549 cells. We also tested combinations of the most active compounds against EV1 in A549 and human immortalized retinal pigment epithelium RPE cells. Results: We confirmed anti-enteroviral activities of pleconaril, rupintrivir, cycloheximide, vemurafenib, remdesivir, emetine, and anisomycin and identified novel synergistic rupintrivir\u2013vemurafenib, vemurafenib\u2013pleconaril and rupintrivir\u2013pleconaril combinations against EV1 infection. Conclusions: Because rupintrivir, vemurafenib, and pleconaril require lower concentrations to inhibit enterovirus replication in vitro when combined, their cocktails may have fewer side effects in vivo and, therefore, should be further explored in preclinical and clinical trials against EV1 and other enterovirus infections.<\/jats:p>","DOI":"10.3390\/v14091866","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T01:50:26Z","timestamp":1661392226000},"page":"1866","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Novel Synergistic Anti-Enteroviral Drug Combinations"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6554-7996","authenticated-orcid":false,"given":"Aleksandr","family":"Ianevski","sequence":"first","affiliation":[{"name":"Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 7028 Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Zusinaite","sequence":"additional","affiliation":[{"name":"Institute of Technology, University of Tartu, 50411 Tartu, Estonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0260-3601","authenticated-orcid":false,"given":"Tanel","family":"Tenson","sequence":"additional","affiliation":[{"name":"Institute of Technology, University of Tartu, 50411 Tartu, Estonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5088-3791","authenticated-orcid":false,"given":"Valentyn","family":"Oksenych","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 7028 Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 7028 Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Egil","family":"Afset","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 7028 Trondheim, Norway"},{"name":"Department of Medical Microbiology, St. Olavs Hospital, 7028 Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8759-1170","authenticated-orcid":false,"given":"Magnar","family":"Bj\u00f8r\u00e5s","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 7028 Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7716-6955","authenticated-orcid":false,"given":"Denis E.","family":"Kainov","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 7028 Trondheim, Norway"},{"name":"Institute of Technology, University of Tartu, 50411 Tartu, Estonia"},{"name":"Institute for Molecular Medicine Finland, University of Helsinki, 00014 Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.apsb.2021.08.017","article-title":"Enterovirus A71 antivirals: Past, present, and future","volume":"12","author":"Wang","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/01.inf.0000059765.92623.70","article-title":"Double blind placebo-controlled trial of pleconaril in infants with enterovirus meningitis","volume":"22","author":"Abzug","year":"2003","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/jpids\/piv015","article-title":"A Randomized, Double-Blind, Placebo-Controlled Trial of Pleconaril for the Treatment of Neonates with Enterovirus Sepsis","volume":"5","author":"Abzug","year":"2016","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1086\/375069","article-title":"Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: Results of 2 double-blind, randomized, placebo-controlled trials","volume":"36","author":"Hayden","year":"2003","journal-title":"Clin. Infect. Dis"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1128\/AAC.47.12.3907-3916.2003","article-title":"Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers","volume":"47","author":"Hayden","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijid.2020.02.018","article-title":"Discovery and development of safe-in-man broad-spectrum antiviral agents","volume":"93","author":"Andersen","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"104112","DOI":"10.1016\/j.isci.2022.104112","article-title":"Mono- and combinational drug therapies for global viral pandemic preparedness","volume":"25","author":"Ianevski","year":"2022","journal-title":"iScience"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Ianevski, A., Yao, R., Biza, S., Zusinaite, E., Mannik, A., Kivi, G., Planken, A., Kurg, K., Tombak, E.M., and Ustav, M. (2020). Identification and Tracking of Antiviral Drug Combinations. Viruses, 12.","DOI":"10.3390\/v12101178"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"W272","DOI":"10.1093\/nar\/gkac348","article-title":"DrugVirus.info 2.0: An integrative data portal for broad-spectrum antivirals (BSA) and BSA-containing drug combinations (BCCs)","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1093\/bioinformatics\/btaa138","article-title":"Breeze: An integrated quality control and data analysis application for high-throughput drug screening","volume":"36","author":"Potdar","year":"2020","journal-title":"Bioinformatics"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1038\/srep05193","article-title":"Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies","volume":"4","author":"Yadav","year":"2014","journal-title":"Sci. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: An interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Andersen, P.I., Krpina, K., Ianevski, A., Shtaida, N., Jo, E., Yang, J., Koit, S., Tenson, T., Hukkanen, V., and Anthonsen, M.W. (2019). Novel Antiviral Activities of Obatoclax, Emetine, Niclosamide, Brequinar, and Homoharringtonine. Viruses, 11.","DOI":"10.20944\/preprints201909.0128.v1"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.antiviral.2018.04.016","article-title":"Novel activities of safe-in-human broad-spectrum antiviral agents","volume":"154","author":"Ianevski","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nchembio.304","article-title":"Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin","volume":"6","author":"Ju","year":"2010","journal-title":"Nat. Chem. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"35324","DOI":"10.1074\/jbc.M112.392142","article-title":"Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza a virus infection","volume":"287","author":"Denisova","year":"2012","journal-title":"J. Biol. Chem."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/9\/1866\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:14:54Z","timestamp":1760141694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/9\/1866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":16,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["v14091866"],"URL":"https:\/\/doi.org\/10.3390\/v14091866","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints202208.0039.v1","asserted-by":"object"}]},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,25]]}}}